Specific medical intervention for diabetic retinopathy
1Department of Basic and Visual Science, Southern California College of Optometry, 2575 Yorba Linda Blvd, Fullerton, CA 92831, USA. jng@scco.edu
Abstract:
Diabetes is a global epidemic and the major complication of diabetes in the eye, diabetic retinopathy, is a leading cause of blindness in several countries. Medical and surgical interventions have been formally investigated for over half a century, but currently only surgical interventions are the standard of care and these treatments are not without significant side effects. Several clinical trials have investigated a protein kinase C (PKC) beta inhibitor as a possible medical intervention for diabetic retinopathy. Though successful in animal studies and smaller clinical studies, the drug showed only marginal success in clinical trials. It is likely that the clinical trials failed for two reasons: (1) enrolling patients with too severe a disease state at baseline and (2) utilizing conventional outcome measures that essentially require severe disease states at baseline for evaluation after a standard follow-up time. Additional clinical trials that enroll patients with earlier stages of diabetic retinopathy and/or utilizing more sensitive surrogate outcomes over a longer follow-up would likely show clinical success of PKC-beta inhibition for the treatment of the diabetic retinopathy.
Insights
Protein kinase C (PKC) beta inhibitors show promise for treating diabetic retinopathy, a leading cause of blindness. Future clinical trials should focus on earlier disease stages and sensitive outcomes for better results.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic retinopathy is a major complication of diabetes and a leading cause of blindness globally.
- Current treatments, primarily surgical, have significant side effects.
- Medical interventions, including protein kinase C (PKC) beta inhibitors, have been explored but yielded limited success.
Purpose of the Study:
- To evaluate the potential of protein kinase C (PKC) beta inhibitors as a medical treatment for diabetic retinopathy.
- To identify reasons for the limited success of previous clinical trials.
- To propose strategies for future clinical trials to demonstrate the efficacy of PKC-beta inhibition.
Main Methods:
- Review of existing clinical trial data for PKC beta inhibitors in diabetic retinopathy.
- Analysis of factors contributing to trial outcomes, including patient disease severity and outcome measures.
- Formulation of recommendations for future study designs.
Main Results:
- Previous clinical trials using PKC beta inhibitors showed only marginal success.
- Trial failures are attributed to enrolling patients with advanced disease and using outcome measures requiring severe baseline conditions.
- Animal and smaller clinical studies indicated potential efficacy.
Conclusions:
- Protein kinase C (PKC) beta inhibition holds potential for treating diabetic retinopathy.
- Future trials should enroll patients with earlier-stage disease.
- Utilizing more sensitive surrogate outcomes and longer follow-up periods are crucial for demonstrating clinical success.
